InfoComm2021
Key Points: Female participation has traditionally been low in AV and Technology Industries. Women find having a lack of role models and unequal growth opportunities as obstacles. Cory Schaeffer believes the AV Industry has a lot to offer women and hopes they come back post-pandemic. Commentary: Female participation in AV and technology industries has…
Latest
Education & EdTech
InfoComm 2021: USC Invested in the Cloud During COVID. Will it Pay Off Long-Term?
Universities have made some sweeping changes and added new capabilities to their offerings after the pandemic forced most schools to adapt. Now networks and systems are preparing to support hybrid and in-person learning, as well as synchronous and asynchronous choices for nontraditional students. While at this year’s InfoComm, we asked Lex Peters, UX Designer…
InfoComm2021
InfoComm 2021: Zoom Leads the Way for the Remote Workforce Revolution
Key Points: A Gitlab report recently showed that 80% of remote workers would recommend working remotely to a friend. Being able to interface with colleagues anywhere enables employers to offer more services to benefit employees. Companies are seeing employees want to strategize how they can get time back into their day to increase personal…
InfoComm2021
MarketScale Counts Down the Best Moments of InfoComm 2021: Part 1
InfoComm returned with a bang in 2021, bringing together innovative companies from across the world of AV in Orlando, Florida. MarketScale was there to bring you the top insights and analysis from some of the brightest minds in the industry. Here are 5 of our best moments of InfoComm 2021. 5: Stadiums Were Not…
InfoComm2021
InfoComm 2021: How Under Armour Uses AV To Keep Employees Connected
Key Points: Nyere Hollingsworth speaks with Tyler Kern on how Under Armour uses AV The virtual presence is just as significant as the physical presence of people in the room. Commentary: InfoComm 2021 may be AV’s big show of the year, but that doesn’t mean it’s not an attractive time and resource investment for…
InfoComm2021
InfoComm 2021: How The AV Industry Is Surviving The Year of COVID
Key Points: The AV industry has faced significant challenges over the past year. The AV industry has found comradery in dealing with the challenges. One of the challenges is the labor shortage that’s impacted the industry. Commentary: InfoComm 2021 is in full swing, finally giving the AV industry the reunion it deserves. Behind every…
InfoComm2021
InfoComm 2021: When the Pandemic Made AVoIP the Standard, Netgear Answered the Call
The MarketScale team is checking in with AV’s biggest names and most innovative product developers at InfoComm 2021, and that includes hearing from the companies that supported mass adoptions of AVoIP infrastructure over the last year, like industry leader Netgear. John Henkel, Pro AV Product Marketing Manager for Netgear Business, joined us at the InfoComm…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…